Neovasc Inc. TSXV: NVC Alexei Marko, CEO Chris Clark, CFO April 2013
Forward-Looking Statements Statements contained herein that are not based on historical or current fact, including without limitation statements containing the words “anticipates,” “believes,” “may,” “continues,” “estimates,” “expects,” and “will” and words of similar import, constitute “forward-looking statements” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Such factors include, among others, the following: general economic and business conditions, both nationally and in the regions in which the Company operates; technology changes; competition; changes in business strategy or development plans; the ability to attract and retain qualified personnel; existing governmental regulations and changes in, or the failure to comply with, governmental regulations; liability and other claims asserted against the Company; and other factors referenced in the Company’s filings with Canadian securities regulators. Given these uncertainties, readers are cautioned not to place undue reliance on such forward-looking statements. The Company does not assume the obligation to update any forward-looking statements. 2
Neovasc in Summary A Canadian small cap medical device company with existing revenues & two development products: Stage Product Growing Revenues Implantable biological tissue & services for transcatheter heart valves & other applications Neovasc Reducer ™ Late Stage for treatment of refractory angina ( CE marked ) Neovasc Tiara ™ Early Stage in preclinical development for treatment of mitral valve disease 3
Reducer Product Treats Refractory Angina • Angina – Constant and severs heart pain caused by inadequate blood flow to heart muscle • Refractory – Angina that cannot be managed through conventional drug, catheter or surgical therapy • Large & growing population of untreatable patients – Improved cardiac care leads to less mortality & more patients with advanced/end-stage disease 4
Reducer Method of Action Reducer modulates outflow of blood from coronary veins, increasing blood flow to ischemic areas Blood flow takes path of Venous back pressure least resistance causes more uniform distribution of blood • Majority of blood flows flow through heart around ischemic muscle areas • Forces more blood into ischemic areas • Relieves angina Reducer implanted in coronary sinus vein 5
Reducer Procedure • Based on 1950’s surgical Beck Procedure • Reported excellent results but is no longer performed due to invasiveness • Reducer achieves same narrowing using modern non-surgical catheter- based techniques • Reducer procedure takes 20 minutes; patient discharged within 24 hours • Safely provides treatment for an otherwise untreatable patient CORONARY SINUS 6
Reducer Clinical Results Compelling clinical data from 1 st human trial (15 patients, 3 centers) • 6-month data published in May 2007 JACC demonstrated safety & significant improvement of angina symptoms • 3 -year follow-up data confirms excellent long-term safety & treatment durability ( presented at ACC, March 2010) Average Echo-Dobutamine Results Average Thalium SPECT Severity Average CCS Class Baseline Baseline 6-mos 3-yrs 6-mos 3-yrs Baseline 6-mos 3-yrs 7
Reducer COSIRA Trial COSIRA (Co ronary Si nus R educer for Treatment of Refractory A ngina) Double-blind, randomized, sham-controlled, multicenter, prospective trial • 110-124 patients • Randomized 1:1 to blinded treatment & sham control arms • Primary endpoint: Efficacy @ 6-months • Sites in Belgium, Canada, UK, Denmark, Sweden & Netherlands • Complete enrollment in Q1 2013 Data will support European market launch & provide pilot data for US FDA trial 8
Reducer Timeline & Market Opportunity Europe • CE mark received November 2011 • Complete COSIRA enrollment in Apr/May 2013 • Collect additional clinical data through registries initiated in Europe & Israel • Launch with distribution partner(s) following completion of COSIRA United States • FDA IDE trial to be initiated following completion of COSIRA study Market size • ~2,000,000 existing “no option” refractory angina patients in US & Europe • ~400,000 new “no option” patients diagnosed annually • ~1,000,000 patients/year treated for “recurrent” angina 9
Biological Tissue and Services Neovasc is a turnkey solution for industry partners developing medical devices that incorporate pericardial tissue Tissue • Proprietary process creates implantable, biocompatible tissue from animal pericardium that retains strength & physical characteristics of natural tissue • Developed specifically for fabricating surgical heart valves • 20+ year implant history, FDA-cleared, CE-marked, EDQM-certified • State-of-the-art laboratories & manufacturing facilities Services • Tissue supply • Development & prototyping services • Pilot & commercial manufacturing 10
Transcatheter Heart Valve Applications Neovasc is the leading independent supplier of biological leaflet material & related services to companies developing transcatheter heart valves • 2011 sales of 1 st generation transcatheter aortic valves $600M • 2012 sales estimated $900M • Next generation devices reach commercialization in 2013/14 • Wider use expected as valves improve • Currently supplying multiple programs • Broad services from simple tissue supply to full OEM valve manufacturing 11
Tiara Mitral Valve Replacement • Neovasc is developing Tiara, a novel transcatheter device for the treatment of mitral regurgitation (MR) • MR is serious & widespread condition that can cause significant disability or death • Significant portion of those with MR are non-surgical candidates • Tiara is a minimally-invasive device - delivered using a catheter inserted through apex of heart to replace the diseased mitral valve 12
Tiara Key Features • Design is specific to mitral anatomy & matches natural shape of mitral annulus • Resists high dislodgment forces during systole • Exerts minimal radial force on mitral annulus • Does not inhibit LV function or obstruct LVOT • Preserves native structures in LV (chordae, papillary muscles) • Implantation does not require rapid pacing & can be completed in less than 5 minutes after obtaining apical access 13
Tiara Development Timeline • Multiple patent applications filed • Refined valves & transapical delivery systems developed • Preclinical testing underway (bench, acute / chronic animal) • Durability (accelerated wear) testing underway • Clinical technique developed & refined through multiple animal implants • Expert medical advisory team assembled & active • Target first human implantation in 2013 14
Tiara Market Opportunity • Success of transcatheter aortic valves has positioned transcatheter mitral valve replacement as major area of industry/clinical interest • 600,000 new patients per year with MR in US & EU • Only 20% of diagnosed patients currently undergo surgery • Minimally invasive mitral valve replacement market potential estimated at >$1B 15
Clinical Opinion Leaders Leaders in interventional cardiology are assisting Neovasc programs • Dr. Shmuel Banai (Tel Aviv Medical Center) • Dr. Elazer Edelman (Harvard – MIT, Cambridge) • Dr. Tim Henry (Minneapolis Heart Institute) • Dr. Marc Jolicoeur (Montreal Heart Institute) • Dr. Martin Leon (Columbia University Medical Center, NYC) • Dr. William O’Neill (Miller School of Medicine, University of Miami) • Dr. Jean-Francois Tanguay (Montreal Heart Institute) • Dr. Stefan Verheye (Antwerp Cardiovascular Institute) • Dr. Chris White (Ochsner Medical Center, New Orleans) 16
Neovasc Looking Forward Continued growth of tissue business • Steady growth in 2013 • Upside potential as customers’ products commercialize in 2014 forward Complete COSIRA trial for Reducer & pilot launch in Europe • Complete COSIRA enrollment in Apr/May 2013 • Release full efficacy data after 6-month follow up in Q4 2013 • Continue controlled EU release through REDUCE registries • Strategic partnership for wider EU launch in 2014 • Develop plan for FDA approval and US market entry with Partner Continued development of Tiara • Target first human study of Tiara in Q4 2013 17
Neovasc Recap Product leader in 3 separate fields • Neovasc Tissue – Growing revenues & significant strategic value • Neovasc Reducer – CE marked & efficacy data in 2013 • Neovasc Tiara – Successful acute animal studies & rapid advance to clinical stage in 2013 Corporate Summary • Clean corporate structure 45.9m share issued, 55.8m fully diluted • Revenue growth of 50% over the last 4 years • $5.8m cash on hand at December 2012 • Additional $4.2m from maturing in-the-money warrants and options in 2013 • Key investors including Frost Group, Gagnon Securities and Peregrine Ventures Public small cap opportunity in rapidly growing transcatheter valve space 18
Thank you 19
Recommend
More recommend
